Continuous versus intermittent antibiotics for bronchiectasis

Tim Donovan; Lambert M Felix; James D Chalmers; Stephen J Milan; Alexander G Mathioudakis; Sally Spencer

doi:10.1002/14651858.CD012733.pub2

Antibióticos continuos versus antibióticos intermitentes para la bronquiectasia

Contraer todo Desplegar todo

Referencias

Referencias de los estudios excluidos de esta revisión

Ir a:

estudios en curso
otras referencias

Aksamit TR, De Soyza A, Operschall E, Bandel T‐J, Krahn U, Montegriffo E, et al. Baseline demographic profile of subjects of the phase 3 RESPIRE 2 trial of ciprofloxacin dry powder for inhalation (DPI) in non‐cystic fibrosis bronchiectasis (NCFB). American Journal of Respiratory and Critical Care Medicine 2016;193:A1768.

Google Scholar

Aksamit T, Bandel TJ, Criollo M, De Soyza A, Elborn JS, Operschall E, et al. The RESPIRE trials: two phase III, randomized, multicentre, placebo‐controlled trials of ciprofloxacin dry powder for inhalation (ciprofloxacin dpi) in non‐cystic fibrosis bronchiectasis. Contemporary Clinical Trials2017; Vol. 58:78‐85.

Google Scholar

Aksamit TR, Bandel T‐J, Criollo M, Elborn JS, Lau M, Operschall E, et al. Respire 2: ciprofloxacin dpi 32.5 mg b.i.d. administered 14 days on/off or 28 days on/off vs. placebo for 48 weeks in patients with non‐cystic fibrosis bronchiectasis (NCFB). American Journal of Respiratory and Critical Care Medicine 2017;195:A7642.

Google Scholar

De Soyza A, Aksamit T, Operschall E, Bandel T‐J, Krahn U, Criollo M, et al. Baseline demographic profile of subjects of the phase 3 RESPIRE 1 trial of ciprofloxacin dry powder for inhalation (DPI) in non‐cystic fibrosis bronchiectasis (NCFB). European Respiratory Journal 2015;46:PA2617.

Google Scholar

De Soyza A, Aksamit TR, Bandel T‐J, Criollo M, Elborn JS, Krahn U, et al. RESPIRE 1: ciprofloxacin DPI 32.5mg b.d. administered 14 day on/off or 28 day on/off vs placebo for 48 weeks in subjects with non‐cystic fibrosis bronchiectasis (NCFB). European Respiratory Journal 2016;48:OA272.

Google Scholar

NCT01764841. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis (non‐cf BE) [Randomized, double‐blind, placebo‐controlled, multicenter study comparing ciprofloxacin dpi 32.5 mg bid (twice a day) intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus placebo to evaluate the time to first pulmonary exacerbation and frequency of exacerbations in subjects with non‐cystic fibrosis bronchiectasis]. clinicaltrials.gov/ct2/show/NCT01764841 (first received 10 January 2013).

NCT02106832. Ciprofloxacin dry powder for inhalation (dpi) in non‐cystic fibrosis bronchiectasis (non‐CF BE) (RESPIRE 2) [Randomized, double‐blind, placebo‐controlled, multicenter study comparing ciprofloxacin dpi 32.5 mg bid (twice a day) intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus placebo to evaluate the time to first pulmonary exacerbation and frequency of exacerbations in subjects with non‐cystic fibrosis bronchiectasis]. clinicaltrials.gov/ct2/show/NCT02106832 (first received 8 April 2014).

Quittner A, De Soyza A, Aksamit TR, Bandel T‐J, Criollo M, Elborn JS, et al. Effects of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) on health‐related quality of life in patients with non‐cystic fibrosis bronchiectasis (NCFB): results from the Phase III RESPIRE 1 study. American Journal of Respiratory and Critical Care Medicine 2017;195:A7303.

Google Scholar

Alberto S, Colongo PG, Brusasco L, Frigerio G. Studies of the clinical and respiratory functional effects of a mucolytic‐antibiotic preparation in chronic bronchopulmonary diseases. Controlled double‐blind single code studies. Minerva Medica 1968;59(53):2995‐3002.

Alekseenko AV, Sokolov SB, Kobrin LI, Opalinskii VN, Lavrent'ev IuA. Direct current in the overall treatment of inflammatory suppurative diseases of the lungs [Voprosy Kurortologii, Fizioterapii, i Lechebonoi]. Fizicheskoi Kultury 1978;2:44‐6.

Google Scholar

Alekseenko AV. Effectiveness of conservative treatment of disseminated forms of chronic inflammatory‐suppurative lung diseases. Terapevticheskii Arkhiv 1980;52(1):57‐9.

Aliberti S, Masefield S, Polverino E, De Soyza A, Loebinger MR, Menendez R, et al. Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration. European Respiratory Journal 2016;48(3):632‐47. [PUBMED: 27288031]

Al‐Mobeireek A, Kambal AM, Al‐Balla SR, Al‐Sawwaf H, Saleemi S. Pseudomonas aeruginosa in hospitalized patients with infective exacerbations of bronchiectasis: clinical and research implications. Annals of Saudi Medicine 1998;18(5):469‐71.

Antoniu S, Azoicai D. Ciprofloxacin dpi in non‐cystic fibrosis bronchiectasis: a phase II randomized study. Expert Opinion on Investigational Drugs 2013;22(5):671‐3.

Cherniack NS, Vosti KL, Dowling HF, Lepper MH, Jackson GG. Long‐term treatment of bronchiectasis and chronic bronchitis; a controlled study of the effects of tetracycline, penicillin, and an oleandomycinpenicillin mixture. Archives of Internal Medicine 1959;103(3):345‐53.

ChiCTR‐IOR‐16008910. Effectiveness of procalcitonin‐guided antibiotic therapy in acute exacerbations of bronchiectasis: a randomized controlled trial. www.chictr.org.cn/showprojen.aspx?proj=15079 (first received 26 July 2016).

Chonabayasi N, Aosima M, Noguchi M, Yoshimura K, Nakatani T, Nakamori Y, et al. T‐3262 in respiratory infections. Chemotherapy1988; Vol. 36:439‐53.

Google Scholar

Choo JM, Abell GCJ, Thomson R, Morgan L, Waterer G, Gordon DL, et al. Impact of long‐term erythromycin therapy on the oropharyngeal microbiome and resistance gene reservoir in non‐cystic fibrosis bronchiectasis. mSphere 2018;3(2):e00103‐18.

Cseri T, Kelemen S. Treatment with sumetrolim in chronic non‐specific respiratory tract infections. Therapia Hungarica 1975;23(3):115‐7.

Currie DC, Garbett ND, Chan KL, Higgs E, Todd H, Nunn AJ, et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis [abstract]. Clinical Research 1987;72(s16):79P.

Google Scholar

Currie DC, Gargett ND, Cole PJ. Penetration of antibiotics into the respiratory tract. British Medical Journal (Clinical Research Ed.) 1987;295(6590):119. [EMBASE: 10.1136/bmj.295.6590.119]

Dimakou K, Kaponi M, Karampitsakos T, Tzouvelekis A, Chrysikos S, Melachroinidou M, et al. Eradication treatment in Non CF bronchiectasis: the effect of inhaled antibiotics (tobramycin and colistin) on patients with pseudomonas aeruginosa. European Respiratory Journal 2017;suppl 61:OA1971.

Google Scholar

Dimakou K, Liapikou A, Triantafilidou C, Chrysikos S, Kaponi M, Melachroinidou M, et al. Non cf bronchiectasis: the effect of inhaled antibiotics (tobramycin and colistin) in patients with pseudomonas aeruginosa in sputum. American Journal of Respiratory and Critical Care Medicine 2017;195:A1518.

Google Scholar

Douglas AC, Somner AR, Marks BL, Grant IWB. Effect of antibiotics on purulent sputum in chronic bronchitis and bronchiectasis. Lancet 1957;273(6988):214‐8.

Hayashi T, Yamada H, Yasuoka A, Sasayama K, Doutsu Y, Kohno S, et al. Basic and clinical studies on cefdinir. Chemotherapy 1989;37(Supplement 2):565‐78.

Google Scholar

Hill SL, Bilton D, Johnson MM, Pye A, Mitchell JL, Stockley RA. Sputum and serum pharmacokinetics of loracarbef (a new carbacephem antibiotic) in patients with bronchiectasis [Abstract]. European Respiratory Journal 1992;5:142s.

Google Scholar

Howie JG. Antibiotics and purulent sputum. British Medical Journal 1976;2(6040):882.

Huang H, Yang P, Wang J, Wu Y, Zi S, Tang J, et al. Investigation into the individualized treatment of traditional chinese medicine through a series of n‐of‐1 trials. Evidence‐based Complementary and Alternative Medicine : ECAM 2018;2018:Article Number: 5813767.

Hughes DT. Use of combinations of trimethoprim and sulfamethoxazole in the treatment of chest infections. Journal of Infectious Diseases 1973;128(Suppl):701‐5.

Hughes DT. Use of combinations of trimethoprim and sulphamethoxazole in the treatment of chest infections. Medical Journal of Australia 1973;1(2):58‐61.

Iglauer E, Wieser O. Parenteral treatment of severe bronchopulmonary infections using trimethoprim and sulfamethoxazole. Wiener Medizinische Wochenschrift (1946)1973; Vol. 123, issue 20:322‐3.

Google Scholar

Inoue Y, Masuyama Y, Dotsu Y, Kaku M, Suyama N, Hayashi T, et al. Basic and clinical studies on 7432‐S. [Japanese]. Chemotherapy 1989;37:285‐97.

Google Scholar

Irabu Y, Tamaki K, Fukuhara H, Nakamura H, Kaneshima H, Shimoij K, et al. Laboratory and clinical studies on cefdinir. [Japanese]. Chemotherapy 1989;37:603‐11.

Google Scholar

Irabu Y, Fukuhara H, Nakamura H, Kaneshima H, Simoji K, Kitsukawa K, et al. Laboratory and clinical studies of ME1207. [Japanese]. Chemotherapy 1992;40:452‐8.

Google Scholar

Juthong S, Eiamsa‐ard S. The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: A double blinded randomized controlled study [Abstract]. European Respiratory Journal 2011;38:819s.

Google Scholar

Kanai J, Tanaka S, Matsumoto T, Noda S. Clinical trial use of phenoxypropyl penicillin. Journal of Antibiotics 1963;16:25‐6.

Google Scholar

Kawano M, Irimajiri K, Higuchi J, Uchiyama T, Tsubura E. Studies on amikacin (BB‐K8), a new aminoglycoside antibiotic (author's transl). Japanese Journal of Antibiotics 1974;27(4):446‐50.

Google Scholar

Kawashima K, Yamamoto H, Kadoya M, Kato M, Nata T, Iida E, et al. Clinical role of Branhamella catarrhalis infection in pulmonary disorders. [Japanese]. Saishin Igaku [Modern Medicine] 1989;44(6):1268‐72.

Google Scholar

Koyama M. ME1207: a clinical study. [Japanese]. Chemotherapy 1992;40:692‐5.

Google Scholar

Krawczyk Z, Gornicka Wilczynska M, Pilarska Machowicz A, Pruszynska S. Comparative evaluation of certain antibiotics and Biceptol preparation in the treatment of chronic bronchial disease exacerbations. [Polish]. Polski Tygodnik Lekarski 1981;36(25):927‐30.

Kudo K, Ishii A, Kabe J. ME1207 in respiratory infections. [Japanese]. Chemotherapy 1992;40:696‐9.

Google Scholar

Kurishima S, Hirose H, Fukui T, Katsu M. Basic and clinical studies on cefclidin. [Japanese]. Chemotherapy 1992;40:273‐9.

Google Scholar

Kuze F, Kurasawa T, Kato M, Kagioka A, Inaba N, Kuroda N, et al. Cefodizime (THR‐221) in respiratory tract infections. [Japanese]. Chemotherapy 1988;36:467‐72.

Google Scholar

Lamotte A. Bronchiectasis [French]. Ouest‐medical 1981;34(14):969‐72.

Google Scholar

Ledson MJ, Cowperthwaite C, Walshaw MJ, Gallagher MJ, Williets T, Hart CA. Nebulised taurolidine and B cepacia bronchiectasis. Thorax 2000;55(1):91‐2.

Lunacharskaia TV, Kopeiko IP. Intratracheal use of morphocycline. [Russian]. Antibiotiki 1968;13(12):1123‐6.

Maekawa N, Tsukuma S, Nakanishi M, Yamashita M, Kanda M. Clinical results of the use of cephaloridine in lung diseases, especially pulmonary tuberculosis. [Japanese]. Journal of Antibiotics. Ser. B 1967;20(2):140‐4.

Google Scholar

Masuno T, Ikeda T, Kishimoto S, Morimoto Y, Tsujimoto T, Igarashi T, et al. A clinical study of cefclidin. Chemotherapy 1992;40:331‐40.

Google Scholar

Matsumoto K, Nagatake T, Shishido H. Laboratory and clinical evaluation of lenampicillin (KBT‐1585) in respiratory infection. [Japanese]. Chemotherapy 1984;32:397‐411.

Google Scholar

Matsumoto M, Koga Y, Ando M, Araki S. Clinical studies on ME1207 in the treatment of respiratory tract infections. [Japanese]. Chemotherapy 1992;40:740‐3.

Google Scholar

Matsuura T, Suzuki K, Yamamoto T. Clinical studies of S‐1108 in elderly patients. Chemotherapy 1993;41:795‐9.

Google Scholar

May JR, Ingold H. Amoxicillin in the treatment of lower respiratory infections. Advances in Clinical Pharmacology 1974;7:85‐90.

Mazzei JA, Vujacich P, Fernandez A, Tanco J. Ciprofloxacin in the treatment of lower respiratory tract infections. Drugs 1993;46:407‐9.

Messens Y, Oger A, Cornette M, Calay G. Double‐blind study of the sulfamethoxazole‐trimethoprim association in the treatment of pulmonary infections. Acta Clinica Belgica 1973;28(2):92‐9.

Milcev M, Ovcarova H, Ivanov S. Antibacterial treatment of anaerobic lung infections. [Bulgarian]. Pnevmologiya i Ftiziatriya 1985;22(3):20‐4.

Google Scholar

Ming O, Yong Li, Zhang W. Efficacy of macrolide and theophylline in the management of bronchiectasis. Respirology 2005;10:A168.

Google Scholar

Molodtsova VP, Fedoseev GB, Gerasin VA. Cleansing of the bronchial tree in treating chronic inflammatory lung diseases. [Russian]. Sovetskaia Meditsina 1980;11(11):90‐2.

Google Scholar

Morrone N, Saito M, Brito VC, Hayashi F. Pulmonary infections in adults: two therapeutics regimens of ofloxacin. Folha Medica 1989;98(4):253‐8.

Google Scholar

Murayama T, Kuze F, Oida K, Nanbu Y, Iwata T, Ikeda N, et al. A clinical study of the effects of ME1207 on respiratory infections [Japanese]. Chemotherapy 1992;40:724‐7.

Google Scholar

Nagy M, Meszaros G. Late results of the conservative treatment of bronchiectasis in adults. [German]. Zeitschrift fur Tuberkulose und Erkrankungen der Thoraxorgane 1968;127(5):283‐90.

Nakagawa Y, Niki Y, Hino J, Kishimoto T, Kawane H, Soejima R. Bacteriological and clinical studies of cefdinir. Chemotherapy1989; Vol. 37:518‐24.

Google Scholar

Nakagawa M, Tsubura E. Clinical study of S‐1108 in respiratory infections. Chemotherapy 1993;41:803‐6.

Google Scholar

Nasu M, Yamazaki T, Yamazaki H, Kuroda Y, Goto Y, Shigeno H, et al. T‐3262 in respiratory tract infections [Japanese]. Chemotherapy 1988;36:699‐709.

Google Scholar

NCT00415350. Bronchiectasis and long term azithromycin treatment [Bronchiectasis and long term azithromycin treatment: a randomised placebo‐controlled trial studying disease modifying effects of immunomodulating treatment]. clinicaltrials.gov/ct2/show/NCT00415350 (first received 22 December 2006).

NCT00524095. Bronchiectasis in chronic obstructive pulmonary disease (COPD) patients: role of prophylaxis [Bronchiectasis in COPD patients : role of prophylaxis with inhaled steroids and antibiotic on the natural history of the disease]. clinicaltrials.gov/ct2/show/NCT00524095 (first received 3 September 2007).

NCT00775138. A study to determine the safety and tolerability of arikace versus placebo in patients who have bronchiectasis [A placebo controlled, randomized, parallel cohort, safety and tolerability study of 2 dose levels of liposomal amikacin for inhalation (Arikace™) in patients with bronchiectasis complicated by chronic infection due to pseudomonas aeruginosa]. clinicaltrials.gov/ct2/show/NCT00775138 (first received 17 October 2008).

NCT00889967. Safety and efficacy study of ciprofloxacin for inhalation in patients with non‐cystic fibrosis bronchiectasis "ORBIT‐1" [An international, multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy, safety, and tolerability of once daily administration of two strengths of ciprofloxacin for inhalation compared with placebo for inhalation in the management of pseudomonas aeruginosa in patients with non cystic fibrosis bronchiectasis]. clinicaltrials.gov/ct2/show/NCT00889967 (first received 29 April 2009).

NCT00930982. Evaluation of cipro inhale in patients with non‐cystic fibrosis bronchiectasis [Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin inhale compared to placebo in patients with non‐cystic fibrosis bronchiectasis]. clinicaltrials.gov/ct2/show/NCT00930982 (first received 2 July 2009).

NCT01313624. A study to see if AZLI (an inhaled antibiotic) is effective in treating adults with non‐cf bronchiectasis ‐ AIR‐BX1 [A phase 3, double‐blind, multicenter, randomized, placebo‐controlled trial evaluating repeated courses of aztreonam for inhalation solution in subjects with non‐cf bronchiectasis and gram‐negative endobronchial infection]. clinicaltrials.gov/ct2/show/NCT01313624 (first received 14 March 2011).

NCT01515007. Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non‐CF Bronchiectasis (ORBIT‐3). ClinicalTrials.gov2012.

Google Scholar

NCT01538667. Study to characterize lung deposition, pharmacokinetics, safety and tolerability of single inhalations of radiolabeled ciprofloxacin dry powder in healthy subjects and patients with chronic lung diseases [Non‐blinded, single dose, single centre trial to assess the pulmonary deposition as well as pharmacokinetics, safety and tolerability of 99mTc labeled ciprofloxacin when delivered as a single dose from a dry powder inhaler to healthy subjects with and without charcoal block and patients suffering from bronchiectasis and COPD]. clinicaltrials.gov/ct2/show/NCT01538667 (first received 24 February 2012).

NCT01761214. Bacteriology and inflammation in bronchiectasis [Bacteriology and sputum and systemic inflammation in steady‐state, acute exacerbation and recovery of bronchiectasis]. clinicaltrials.gov/ct2/show/NCT01761214 (first received 4 January 2013).

NCT02035488. Pharmacokinetic evaluation and tolerability of dry powder tobramycin by a novel device in patients with non cystic fibrosis bronchiectasis. clinicaltrials.gov/ct2/show/NCT02035488 (first received 14 January 2014).

NCT02047773. Bacterial load guided therapy for severe bronchiectasis exacerbations [Bacterial load guided therapy for severe exacerbations of bronchiectasis requiring intravenous antibiotic therapy‐ BLT Br IV study]. clinicaltrials.gov/ct2/show/NCT02047773 (first received 28 January 2014).

NCT02081963. Combined administration of nebulized amikacin in patients with acute exacerbation of non‐cystic fibrosis bronchiectasis [A randomized, controlled study of combined administration of nebulized amikacin in patients with acute exacerbation of non‐cystic fibrosis bronchiectasis]. clinicaltrials.gov/ct2/show/NCT02081963 (first received 7 March 2014).

NCT02102152. Efficacy & tolerability of tobramycin podhaler in bronchiectasis patients with chronic pseudomonas aeruginosa infection. clinicaltrials.gov/ct2/show/NCT02102152 (first received 2 April 2014).

NCT02104245. Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non‐CF Bronchiectasis (ORBIT‐4). ClinicalTrials.gov2014.

Google Scholar

NCT02107274. Efficacy of azithromycin in treatment of bronchiectasis. clinicaltrials.gov/ct2/show/NCT02107274 (first received 8 April 2014).

NCT02315547. Sputum microbiota and the association with clinical parameters in steady‐state, acute exacerbation and convalescence of bronchiectasis (BISER‐2). clinicaltrials.gov/ct2/show/NCT02315547 (first received 12 December 2014).

NCT02491723. Macrolide mediates pulmonary infection of pseudomonas aeruginosa [Macrolide mediates pulmonary infection of pseudomonas aeruginosa via NLRC4 inflammasome signaling pathway]. clinicaltrials.gov/ct2/show/NCT02491723 (first received 8 July 2015).

NCT02509091. Therapy of bronchoalveolar lavage and local amikacin injection in patients with acute exacerbation of bronchiectasis [Clinical efficacy and safety of therapy of bronchoalveolar lavage and local amikacin injection in patients with acute exacerbation of bronchiectasis:an open‐label randomized parallel controlled study]. clinicaltrials.gov/ct2/show/NCT02509091 (first received 27 July 2015).

NCT02657473. Inhaled nebulized tobramycin in non‐cystic fibrosis bronchiectasis (BATTLE) [Long‐term inhaled nebulized tobramycin in patients with non‐cystic fibrosis bronchiectasis. A randomized placebo controlled trial. The BATTLE study bronchiectasis and tobramycin solution inhalation therapy]. clinicaltrials.gov/ct2/show/NCT02657473 (first received 15 January 2016).

NCT02661438. Summative usability study of ciprofloxacin dry powder for inhalation using placebo [Multicenter summative usability study of ciprofloxacin dry powder for inhalation in subjects with non‐cystic fibrosis bronchiectasis (NCFB) or chronic obstructive pulmonary disease (COPD) using matching placebo]. clinicaltrials.gov/ct2/show/NCT02661438 (first received 22 January 2015).

NCT03058718. Procalcitonin‐guided antibiotic therapy in bronchiectasis [Effectiveness of procalcitonin‐guided antibiotic therapy in acute exacerbations of bronchiectasis: a randomized controlled trial]. clinicaltrials.gov/ct2/show/NCT03058718 (first received 23 February 2017).

NCT03093974. Trial in non‐cystic fibrosis bronchiectasis patients with chronic lung infections treated with colistimethate sodium (PROMIS‐I). clinicaltrials.gov/ct2/show/NCT03093974 (first received 28 March 2017).

Trial in non‐cystic fibrosis bronchiectasis patients with chronic lung infections treated with colistimethate sodium (PROMIS‐2). https://clinicaltrials.gov/show/NCT03460704.

Neumayr A, Stoefler G. Clinical trials of the new antibiotic, rifamycin sv: preliminary report. Chemotherapy 1963;12:437‐8.

Google Scholar

O'Donnell AE, Bilton D, Serisier D, Wanner A, Froehlich J, Bruinenberg P, et al. ORBIT‐3 and ORBIT‐4: design of a phase 3 program to investigate safety and efficacy of pulmaquin in non‐cystic fibrosis bronchiectasis (NCFBE) patients chronically colonized with pseudomonas aeruginosa (PA). American Journal of Respiratory and Critical Care Medicine 2016;193:A1775.

Google Scholar

Obana M, Matsuoka Y, Irimajiri S, Yoshioka I. Clinical study on ME1207 in respiratory tract infections. Chemotherapy 1992;40:700‐2.

Google Scholar

Odagiri S, Suzuki K, Murohashi K, Takahashi H, Takahashi K. Clinical study of ME 1207 in respiratory tract infections. Chemotherapy 1992;40:703‐7.

Google Scholar

Oizumi K, Watanabe A, Konno K, Hayashi I, Kawamorida K, Nagai K, et al. Therapeutic effect of amikacin for infections with gram‐negative bacilli, especially for stubborn respiratory infections (author's transl). [Japanese]. Japanese Journal of Antibiotics 1978;31(1):15‐23.

Google Scholar

Pezza A, Giacomelli P, Montella R, Casino G. Clinical study of a new cephalosporin: ceftriaxone (RO 13‐9904) in resurgent acute and chronic bronchopneumopathies. [Italian]. Archivio Monaldi per la Tisiologia e le Malattie dell'Apparato Respiratorio 1983;38(1):17‐24.

Rikitomi N, Shishido H, Nagatake T, Mbaki U, Matsumoto K. Preclinical and clinical studies on TE‐031 (A‐56268) in treatment of bacterial respiratory tract infections. Chemotherapy 1988;36:715‐28.

Google Scholar

Saito A, Kusano N, Fukuhara H, Soejima R, Nakahama C, Niki Y, et al. A study of the clinical effects of clindamycin on respiratory infections ‐ Focusing on inhibition of beta‐lactamase production. [Japanese]. Chemotherapy 1993;41(11):1232‐45.

Google Scholar

Santiveri C, Orriols R, Roig J, Balcells E, Bellver P, Ferrer A, et al. Effectiveness of inhaled antibiotic treatment for pseudomonas aeruginosa in outpatients with colonized bronchiectasis without mucoviscidosis. Archivos de Bronconeumologia 1995;31:42.

Google Scholar

Schulz G. Comparative studies on the toxicity of tetracyclines and chloramphenicol in the treatment of nonspecific bronchopulmonary infections. [German]. Zeitschrift fur Erkrankungen der Atmungsorgane Mit Folia Bronchologica 1972;136(2):185‐96.

Serisier DJ, Thompson PJ, Greville H, Kolbe J, Bruinenberg PR. Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE) [Abstract]. European Respiratory Journal 2011;28:334s.

Google Scholar

Burr LD, Rogers GB, Chen AC‐H, Hamilton BR, Pool GF, Taylor SL, et al. Macrolide treatment inhibits pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis: an analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society 2016;13:1697‐1703.

Rogers GB, Bruce KD, Martin ML, Burr LD, Serisier DJ. Corrections to, The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine 2015;3(4):e15. [DOI: 10.1016/S2213‐2600(15)00102‐2]

Serisier DJ, Bowler SD, McGuckin M, Chen A, Lourie R, Martin ML. The bronchiectasis and low‐dose erythromycin study (BLESS) [Abstract]. American Journal of Respiratory and Critical Care Medicine 2012;185:A6862.

Google Scholar

Shigeno Y, Masaki M, Nakazato H. Laboratory and clinical studies on lenampicillin (KBT‐1585) a new penicillin antibiotic. [Japanese]. Chemotherapy 1984;32:382‐96.

Google Scholar

Shimada K, Inamatsu T, Fukayama M, Kato A, Adachi K, Sasaki M, et al. Antimicrobial activity and clinical evaluation of NY‐198. Chemotherapy1988; Vol. 36:537‐44.

Google Scholar

Shimokata K, Sakai S, Senda Y, Nishiwaki K, Yamaoto M, Murate T, et al. Evaluation of cefclidin on respiratory tract infections. Chemotherapy 1992;40:748‐52.

Google Scholar

Shishido H, Furukawa K, Nagai H, Kawakami K, Kono H. Oral levofloxacin 600 mg and 300 mg daily doses in difficult‐to‐treat respiratory infections. Drugs 1995;49:433‐5.

Simioli F, Sorrentino N, Martino M, Porzio M, Stanziola AA, Molino A, et al. Open label case‐control study to assess Pidotimod efficacy in Non CF Bronchiectasis Disease: a pilot study. European Respiratory Journal 2017;50:PA4063.

Google Scholar

Soejima R, Niki Y, Hino J, Nakagawa Y, Sumi M, Kishimoto T, et al. Clinical studies on TE‐031 (A‐56268). Chemotherapy 1988;36:673‐8.

Google Scholar

Suga M, Ando M, Tanaka F, Ito K, Sakata T, Sugimoto M, et al. Clinical studies of T‐3262 in respiratory tract infection. [Japanese]. Chemotherapy 1988;36:694‐8.

Google Scholar

Sun JX, Xi MJ, Tu CL, Liu RR, Hu JR, Zhu LP. Efficacy of Juqin mixture aerosol inhalation treatment of bronchiectasis. Chinese Journal of Experimental Traditional Medical Formulae 2015;21:167‐70.

Google Scholar

Suyama N, Inoue Y, Masaki M, Mashimoto H, Masuyama Y, Dohtsu Y, et al. Laboratory and clinical studies on cefodizime (THR‐221). Chemotherapy 1988;36:529‐44.

Google Scholar

Tagaya E, Tamaoki A, Kondo M, Nakada J, Nagai A. Effect and action mechanism of short‐term administration of clarithromycin for airway hypersecretion. [Japanese]. Japanese Journal of Antibiotics 2001;54:33‐35.

Google Scholar

Tamura S, Tokita K, Tsutsumi Z, Ohkawa T, Fujioka H, Kurabori J, et al. Clinical studies on cefclidin. Chemotherapy 1992;40:737‐47.

Google Scholar

Tanimoto H, Obara K, Komatuzaki K, Tanabe O, Okamura T. A clinical study on ME1207 in respiratory infections. Chemotherapy 1992;40:683‐5.

Google Scholar

Tanimoto H, Obara K, Tateishi O, Okamura T. Clinical studies on S‐1108 in respiratory infections. Chemotherapy 1993;41:751‐4.

Google Scholar

Twiss J, Byrnes C. Nebulised antibiotics reduce symptoms, bacterial density and oral antibiotic usage in children with non cystic fibrosis bronchiectasis [Abstract]. Respirology 2009;14:A76.

Google Scholar

Wada K, Kawashima T, Tukada H, Igarashi K, Arakawa M. Clinical study of ME1207. Chemotherapy 1992;40:708‐10.

Google Scholar

Watanabe K, Koyama M, Yokozawa M. Basic and clinical studies on cefotiam hexetil. Chemotherapy 1988;36:311‐22.

Google Scholar

Watanabe A. Once daily versus every two week multidose ofloxacin in patients with acute exacerbations of chronic respiratory disease. Infection 1991;19:S384‐7.

Watanabe A, Oizumi K, Motomiya M, Nukiwa T. Daily single‐dose regimen and alternate‐two‐week triple‐dose/day regimen of oral ofloxacin for the prophylaxis and control of exacerbations of chronic respiratory tract infections. Tohoku Journal of Experimental Medicine 1995;176(1):25‐33.

Weston M. A clinical trial of fusafungin. British Journal of Diseases of the Chest1966; Vol. 60, issue 2:104‐6.

Google Scholar

Wilson R, Welte T, Polverino E, De Soyza A, Greville HW, O’Donnell AE, et al. Efficacy and safety of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis [Abstract]. European Respiratory Journal 2011;38(55):334s.

Google Scholar

Wong M, Lam J, Ip S, Lam CL, Tsang KW. Quality of life effect of levofloxacin compared to ceftazidime treatment in infective exacerbation of bronchiectasis [Abstract]. Respirology 2004;9:A135.

Google Scholar

Yamada H, Katoh O, Aoki Y, Nakata H, Yamaguchi M. Clinical study on S‐1108 in respiratory tract infections. Chemotherapy 1993;41:816‐9.

Google Scholar

Yoshida T, Tao M, Tanaka H, Morito T, Nagatake T, Shishido H, et al. Basic and clinical evaluation of cefdinir, a new oral cephem. Chemotherapy 1989;37:579‐90.

Google Scholar

Zegaya M, Belkahia Ch, Ladjimi S. Study of doxycycline in pleuropulmonary affections. La Tunisie Medicale 1981;59(5):401‐7.

Referencias de los estudios en curso

Ir a:

estudios excluidos
otras referencias

Dose‐finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non‐Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection (iBEST‐1). Ongoing study 2 February 2017.

Referencias adicionales

Ir a:

estudios excluidos
estudios en curso

Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013;309(12):1251‐9. [PUBMED: 23532241]

Barker AF, O'Donnell AE, Flume P, Thompson PJ, Ruzi JD, de Gracia J, et al. Aztreonam for inhalation solution in patients with non‐cystic fibrosis bronchiectasis (AIR‐BX1 and AIR‐BX2): two randomised double‐blind, placebo‐controlled phase 3 trials. Lancet 2014;2(9):738‐49. [PUBMED: 25154045]

Bibby S, Milne R, Beasley R. Hospital admissions for non‐cystic fibrosis bronchiectasis in New Zealand. New Zealand Medical Journal 2015;128(1421):30‐8.

Google Scholar

Brodt AM, Stovold E, Zhang L. Inhaled antibiotics for stable non‐cystic fibrosis bronchiectasis: a systematic review. European Respiratory Journal 2014;44(2):382‐93. [PUBMED: 24925920]

Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short‐ and long‐term antibiotic treatment reduces airway and systemic inflammation in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine 2012;186(7):657‐65. [PUBMED: 22744718]

Chalmers JD, Hill AT. Mechanisms of immune dysfunction and bacterial persistence in non‐cystic fibrosis bronchiectasis. Molecular Immunology 2013;55(1):27‐34. [PUBMED: 23088941]

Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, et al. The bronchiectasis severity index. An international derivation and validation study. American Journal of Respiratory and Critical Care Medicine 2014;189(5):576‐85. [PUBMED: 24328736]

Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. European Respiratory Journal 2015;45(5):1446‐62. [PUBMED: 25792635]

Chang AB, Grimwood K, Mulholland EK, Torzillo PJ. Bronchiectasis in indigenous children in remote Australian communities. Medical Journal of Australia 2002;177(4):200‐4. [PUBMED: 12175325]

Chang AB, Bell SC, Byrnes CA, Grimwood K, Holmes PW, King PT, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Medical Journal of Australia 2010;193(6):356‐65. [PUBMED: 20854242]

Cole PJ. Inflammation: a two‐edged sword ‐ the model of bronchiectasis. European Journal of Respiratory Diseases. Supplement 1986;147:6‐15. [PUBMED: 3533593]

Cole P. The damaging role of bacteria in chronic lung infection. Journal of Antimicrobial Chemotherapy 1997;40 Suppl A:5‐10. [PUBMED: 9484867]

de la Rosa D, Martínez‐García MA, Olveira C, Girón R, Máiz L, Prados C. Annual direct medical costs of bronchiectasis treatment: Impact of severity, exacerbations, chronic bronchial colonization and chronic obstructive pulmonary disease coexistence. Chronic Respiratory Disease 2016;13(4):361‐71. [PUBMED: 27072020]

Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356(9237):1255‐9. [PUBMED: 11072960]

Elborn JS, Vataire A‐L, Fukushima A, Aballea S, Khemiri A, Moore C, et al. Comparison of inhaled antibiotics for the treatment of chronic pseudomonas aeruginosa lung Infection in patients with cystic fibrosis: systematic literature review and network meta‐analysis. Clinical Therapeutics 2016;8(8):1‐23.

Gibson GJ, Loddenkemper R, Sibille Y, Lundbäck B, editor(s). European Lung White Book: Respiratory Health and Disease in Europe. European Lung White Book: Respiratory Health and Disease in Europe. European Respiratory Society, 2013. [www.erswhitebook.org]

Evans SA, Turner SM, Bosch BJ, Hardy CC, Woodhead MA. Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. European Respiratory Journal 1996;9(8):1601‐4. [PUBMED: 8866579]

Finch S, McDonnell MJ, Abo‐Leyah H, Aliberti S, Chalmers JD. A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Annals of the American Thoracic Society 2015;12(11):1602‐11. [PUBMED: 26356317]

Foweraker J, Wat D. Microbiology of non‐CF bronchiectasis [Bronchiectasis]. In: Floto RA, Haworth CS editor(s). European Respiratory Society Monographs. Vol. 52, European Respiratory Society, 2011:68‐96.

Goeminne PC, De Soyza A. Bronchiectasis: how to be an orphan with many parents?. European Respiratory Journal 2016;47(1):10‐3. [PUBMED: 26721955]

McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 30 January 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.

Habesoglu MA, Ugurlu AO, Eyuboglu FO. Clinical, radiologic, and functional evaluation of 304 patients with bronchiectasis. Annals of Thoracic Medicine 2011;6(3):131‐6. [PUBMED: 21760844]

Hansen MP, Thorning S, Aronson JK, Beller EM, Glasziou PP, Hoffmann TC, et al. Adverse events in patients taking macrolide antibiotics versus placebo for any indication. Cochrane Database of Systematic Reviews 2015, Issue 8. [DOI: 10.1002/14651858.CD011825]

Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. American Journal of Respiratory and Critical Care Medicine 2014;189(8):975‐82. [PUBMED: 24625200]

Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Hill AT, Haworth CS, Aliberti S, Barker A, Blasi F, Boersma W, et al. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. European Respiratory Journal 2017;49(6):pii: 1700051.

Hnin K, Nguyen C, Carson KV, Evans DJ, Greenstone M, Smith BJ. Prolonged antibiotics for non‐cystic fibrosis bronchiectasis in children and adults. Cochrane Database of Systematic Reviews 2015, Issue 8. [DOI: 10.1002/14651858.CD001392.pub3]

Hui C, Lin MC, Jao MS, Liu TC, Wu RG. Previous antibiotic exposure and evolution of antibiotic resistance in mechanically ventilated patients with nosocomial infections. Journal of Critical Care 2013;28(5):728‐34. [DOI: 10.1016/j.jcrc.2013.04.008]

Joish VN, Spilsbury‐Cantalupo M, Operschall E, Luong B, Boklage S. Economic burden of non‐cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective. Applied Health Economics and Health Policy 2013;11(3):299‐304. [PUBMED: 23580074]

Kapur N, Masters IB, Newcombe P, Chang AB. The burden of disease in pediatric non‐cystic fibrosis bronchiectasis. Chest 2012;141(4):1018‐24. [PUBMED: 21885727]

Littlewood KJ, Higashi K, Jansen JP, Capkun‐Niggli G, Balp MM, Doering G, et al. A network meta‐analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis. Journal of Cystic Fibrosis 2012;11(5):419‐26. [DOI: 10.1016/j.jcf.2012.03.010]

Martínez‐García MA, Soler‐Cataluña JJ, Perpìñá‐Tordera M, Román‐Sánchez P, Soriano J. Factors associated with lung function decline in adult patients with stable non‐cystic fibrosis bronchiectasis. Chest 2007;132(5):1565‐72. [PUBMED: 17998359]

Martínez‐García MÁ, Máiz L, Olveira C, Girón RM, de la Rosa D, Blanco M. Spanish guidelines on treatment of bronchiectasis in adults. Archivos de Bronconeumología (English Edition) 2018;54(2):88‐98. [DOI: 10.1016/j.arbres.2017.07.016]

McCullough AR, Tunney MM, Quittner AL, Elborn JS, Bradley JM, Hughes CM. Treatment adherence and health outcomes in patients with bronchiectasis. BMC Pulmonary Medicine 2014;14:107. [PUBMED: 24980161]

Melnyk AH, Alex Wong A, Kassen R. The fitness costs of antibiotic resistance mutations. Evolutionary Applications 2015;8(3):273–83.

Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLoS Medicine 2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097]

Murray MP, Govan JRW, Doherty CJ, Simpson AJ, Wilkinson TS, Chalmers JD, et al. A randomized controlled trial of nebulized gentamicinin non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine 2011;183:491–9.

Pasteur MC, Bilton D, Hill AT, British Thoracic Society Bronchiectasis (non‐CF) Guideline Group. British Thoracic Society Guidelines for non‐CF bronchiectasis. Thorax 2010;65(Suppl1):i1–58.

Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. European Respiratory Journal 2017;50(3):pii: 1700629. [DOI: 10.1183/13993003.00629‐2017]

Quint JK, Millett ER, Joshi M, Navaratnam V, Thomas SL, Hurst JR, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population‐based cohort study. European Respiratory Journal 2016;47(1):186‐93. [PUBMED: 26541539]

Redondo M, Keyt H, Dhar R, Chalmers JD. Global impact of bronchiectasis and cystic fibrosis. Breathe 2016;12(3):222‐35.

Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

Ringshausen FC, de Roux A, Diel R, Hohmann D, Welte T, Rademacher J. Bronchiectasis in Germany: a population‐based estimation of disease prevalence. European Respiratory Journal 2015;46(6):1805‐7. [PUBMED: 26293498]

Roberts HJ, Hubbard R. Trends in bronchiectasis mortality in England and Wales. Respiratory Medicine 2010;104:981‐5.

Rogers GB, Zain NM, Bruce KD, Burr LD, Chen AC, Rivett DW, et al. A novel microbiota stratification system predicts future exacerbations in bronchiectasis. Annals of the American Thoracic Society 2014;11(4):496‐503. [PUBMED: 24592925]

Seitz AE, Olivier KN, Steiner CA, Montes de Oca R, Holland SM, Prevots DR. Trends and burden of bronchiectasis‐associated hospitalizations in the United States, 1993‐2006. Chest 2010;138(4):944‐9. [PUBMED: 20435655]

Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013;309(12):1260‐7. [PUBMED: 23532242]

Twiss J, Metcalfe R, Edwards E, Byrnes C. New Zealand national incidence of bronchiectasis "too high" for a developed country. Archives of Disease in Childhood 2005;90(7):737‐40. [PUBMED: 15871981]

Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clinical Pulmonary Medicine 2005;12(4):205‐9.

Wilson CB, Jones PW, O'Leary CJ, Hansell DM, Cole PJ, Wilson R. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. European Respiratory Journal 1997;10(8):1754‐60. [PUBMED: 9272915]

Wilson R, Welte T, Polverino E, De Soyza A, Greville H, O'Donnell A, et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal 2013;41:1107‐115.

Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet 2012;380(9842):660‐7. [PUBMED: 22901887]

Characteristics of studies

Characteristics of excluded studies [ordered by study ID]

Ir a:

estudios en curso

Study	Reason for exclusion
Aksamit 2016	Comparison between ciprofloxacin versus placebo
Aksamit 2017	Comparison between ciprofloxacin (intermittent for 28 days) versus ciprofloxacin (intermittent for 14 days) versus placebo
Al‐Mobeireek 1998	Study to determine the range and sensitivity of bacterial pathogens in infective exacerbations of bronchiectasis
Alberto 1968	Randomised comparison of thiamphenicol glycinate plus acetylcysteine (FZ280E) versus thiamphenicol glycinate in chronic bronchopulmonary disease
Alekseenko 1978	Comparison between antibiotics with direct current intervention versus antibiotics alone in the treatment of inflammatory suppurative diseases of the lungs
Alekseenko 1980	Not a randomised trial. Study focusing on antibiotics and bronchial sanitations
Aliberti 2016	Not a randomised trial. Consensus statement on the management of bronchiectasis
Antoniu 2013	Comparison between ciprofloxacin versus placeb
Cherniack 1959	Not a randomised trial. Comparison among placebo versus tetracycline versus oleandomycin‐penicillin versus penicillin
ChiCTR‐IOR‐16008910 2016	Comparison between procalcitonin versus control (conventional treatment). Study yet to be completed in 2017
Chonabayasi 1988	Not a randomised trial. Before and after comparison of T‐3262 in respiratory infections
Choo 2018	Comparison between erythromycin versus placebo
Cseri 1975	No indication of randomisation. Comparison between sumetrolim versus oxytetracycline for chronic non‐specific respiratory tract infections
Currie 1987	Comparison between amoxycillin versus placebo
Dimakou 2017	Comparison between tobramycin versus colistin
Douglas 1957	Comparison between chloramphenicol versus oxytetracycline
Hayashi 1989	Not a randomised trial. Evaluation of cefdinir in the treatment of pneumonia
Hill 1992	Comparison between 200 mg twice daily versus 400 mg twice daily of loracarbef (LY 163892).
Howie 1976	Letter
Huang 2018	Comparison between herbal decoction with standard decoction
Hughes 1973	Comparison between trimethoprim and ampicillin
Iglauer 1973	Comparison between trimethoprim versus sulphamethoxazol
Inoue 1989	Not a randomised trial. Evaluation of 7432‐S
Irabu 1989	Not a randomised trial. Evaluation of cefdinir
Irabu 1992	Not a randomised trial. Evaluation of ME1207
Juthong 2011	Comparison between roxithromycin versus placebo
Kanai 1963	Spectrophotometric examination of the respiratory chain
Kawano 1974	Comparison between 200 mg versus 400 mg of amikacin
Kawashima 1989	Not a randomised trial. Observational study of branhamella catarrhalis infection in pulmonary disorders
Koyama 1992	Not a randomised trial. Evaluation of ME1207
Krawczyk 1981	Not a randomised trial. Evaluation of antibiotics and biceptol preparation
Kudo 1992	Not a randomised trial. Evaluation of ME1207
Kurishima 1992	Not a randomised trial. Evaluation of cefclidin
Kuze 1988	Not a randomised trial. Evaluation of cefodizime (THR‐221) in respiratory tract infections
Lamotte 1981	Not a randomised trial. Overview of bronchiectasis
Ledson 2000	Not a randomised trial. N of 1 study of nebulised taurolidine
Lunacharskaia 1968	Evaluation of intratracheal administration of morphocycline
Maekawa 1967	Study did not include participants with bronchiectasis
Masuno 1992	Not a randomised trial. Evaluation of cefclidin
Matsumoto 1984	Not a randomised trial. Evaluation of lenampicillin (KBT‐1585) in respiratory infection
Matsumoto 1992	Not a randomised trial. Evaluation of ME1207 in the treatment of respiratory tract infection
Matsuura 1993	Not a randomised trial. Evaluation of S‐1108 in elderly patients
May 1974	Comparison between amoxicillin versus ampicillin
Mazzei 1993	Not a randomised trial. Evaluation of ciprofloxacin for lower respiratory tract infections
Messens 1973	Comparison between sulfamethoxazoletrimethoprim versus demethylchlortetracycline in the treatment of pulmonary infections
Milcev 1985	Focus of this before and after comparison was on anaerobic pulmonary infections and their resistance to antibiotics
Ming 2005	Comparison between macrolide with theophylline versus 'necessary antibiotics'
Molodtsova 1980	Evaluation of penicillin, streptomycin, monomycin, levomycetin zeporin, chemotripcin and gigrolitin
Morrone 1989	Participants were randomised to receive 400 mg versus 800 mg of Ofloxacin, two doses per day for 10 days for a total of 400 mg per day or 800 mg per day. Comparison therefore not intermittent versus continuous
Murayama 1992	Not a randomised trial. Evaluation of ME1207 for respiratory infections
Nagy 1968	Not a randomised trial
Nakagawa 1989	Not a randomised trial. Evaluation of cefdinir in respiratory tract infections
Nakagawa 1993	Not a randomised trial
Nasu 1988	Not a randomised trial. Evaluation of T‐3262 in respiratory tract infections
NCT00415350	Comparison between azithromycin versus placebo
NCT00524095	Comparison between fluticasone versus azithromycin (study terminated and did not proceed to treatment phase
NCT00775138	Comparison between 280 mg versus 560 mg arikace versus placebo
NCT00889967	Comparison between ciprofloxacin versus placebo
NCT00930982	Comparison between ciprofloxacin versus placebo
NCT01313624	Comparison between aztreonam versus placebo
NCT01515007	Comparison between iprofloxacin for Inhalation versus placebo liposomes for inhalation
NCT01538667	Evaluation of lung deposition, pharmacokinetics, safety and tolerability of ciprofloxacin dry powder
NCT01761214	Not a randomised trial. Evaluation of fluroquinolones
NCT02035488	Not a randomised trial. Evaluation of tobramycin
NCT02047773	Evaluation of bacterial load guided therapy
NCT02081963	Comparison between amikacin and normal saline
NCT02102152	Comparison between tobramycin versus placebo
NCT02104245	Comparison between pulmaquin versus placebo
NCT02107274	Comparison between azithromycin versus placebo
NCT02315547	Not a randomised trial. Comparison between bronchiectasis patients and healthy participants
NCT02491723	Not a randomised trial. Evaluation of azithromycin
NCT02509091	Fundamental treatment combining with the therapy of bronchoalveolar lavage and local amikacin injection versus fundamental treatment alone
NCT02657473	Comparison between tobramycin inhalation solution and saline inhalation solution
NCT02661438	Not a randomised trial. Evaluation of ciprofloxacin
NCT03058718	Evaluation of procalcitonin‐guided antibiotic therapy
NCT03093974	Comparison between colistimethate sodium versus saline solution
NCT03460704	Comparison between colistimethate sodium versus saline Solution
Neumayr 1963	Not a randomised trial
O'Donnell 2016	Comparison of Pulmaquin versus placebo
Obana 1992	Not a randomised controlled trial. Evaluation of ME1207 in respiratory tract infections
Odagiri 1992	Not a randomised controlled trial. Evaluation of ME1207 in respiratory tract infections
Oizumi 1978	Not a randomised controlled trial. Evaluation of amikacin in urinary and respiratory tract infections
Pezza 1983	Not a randomised trial. Evaluation of ceftriaxone in pneumonia with acute exacerbations
Rikitomi 1988	Not a randomised controlled trial. Evaluation of TE‐031 (A‐56268) in treatment of bacterial respiratory tract infections
Saito 1993	Evaluation of the clinical effects of clindamycin on respiratory infections
Santiveri 1995	Evaulation of inhaled antibiotic treatment for pseudomonas aeruginosa
Schulz 1972	Evaluation of chloramphicol and tetrazycline
Serisier 2011	Comparison between DRCFI (a novel liposomal formulation) versus placebo
Serisier 2012	Comparison between erythromycin versus placebo
Shigeno 1984	Not a randomised controlled trial. Evaluation of lenampicillin (KBT‐1585)
Shimada 1988	Not a randomised controlled trial. Evaluation of NY‐198 in urinary and respiratory tract infections
Shimokata 1992	Not a randomised controlled trial. Evaluation of cefclidin on respiratory tract infections
Shishido 1995	Comparison between 100 mg and 200 mg levofloxacin
Simioli 2017	Comparison between pidotimod 800 mg OD versus no treatment
Soejima 1988	Not a randomised controlled trial. Evaluation of TE‐031 (A‐56268)
Suga 1988	Not a randomised controlled trial. Evaluation of T‐3262 in respiratory tract infection
Sun 2015	Juqin mixture aerosol inhalation + standard care versus standard care alone
Suyama 1988	Not a randomised controlled trial. Evaluation of T‐3262 cefodizime (THR‐221)
Tagaya 2001	Not a randomised controlled trial. Comparison between clarithromycin versus ammoxicilin
Tamura 1992	Full review of this study not available. However the intervention is not used in clinical practice
Tanimoto 1992	Not a randomised controlled trial. Evaluation of ME 1207 in the treatment of respiratory infections
Tanimoto 1993	Not a randomised controlled trial. Evaluation of S‐1108 in the treatment of respiratory infections
Twiss 2009	Comparison between nebulised gentamicin versus placebo
Wada 1992	Not a randomised controlled trial and not participants with bronchiectasis. Respiratory tract infections
Watanabe 1988	Not a randomised controlled trial and not participants with bronchiectasis
Watanabe 1991	Not a randomised controlled trial
Watanabe 1995	Not a randomised controlled trial
Weston 1966	Not a randomised controlled trial and not participants with bronchiectasis. Chronic bronchitis
Wilson 2011	Comparison with placebo
Wong 2004	Comparison between levofloxacin versus ceftazidime
Yamada 1993	Not a randomised controlled trial and not participants with bronchiectasis.
Yoshida 1989	Not a randomised controlled trial and not participants with bronchiectasis.
Zegaya 1981	Not a randomised controlled trial. Evaluation of doxycycline in pleuropulmonary affections

Characteristics of ongoing studies [ordered by study ID]

Ir a:

estudios excluidos

NCT02712983

Trial name or title	Dose‐finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non‐Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection (iBEST‐1)
Methods	Parallel group randomized trial
Participants	Patients with non‐cystic fibrosis bronchiectasis and pulmonary P Aeruginosa infection
Interventions	tobramycin inhalation powder (TIP) dose and placebo, 3 dose regimens
Outcomes	P aeruginosa density in sputum
Starting date	2 February 2017
Contact information	Novartis Pharmaceuticals: email: [email protected]
Notes	Estimated completion date: 10 September 2018

Figure 1

Study flow diagram.

Ir a la figura de la revisiónAbrir en una pestaña nueva

	Idioma de la Revisión Cochrane Escoja su idioma de preferencia para las revisiones Cochrane y otros contenidos. Las secciones sin una traducción aparecerán en inglés.

	Idioma de la web Escoja su idioma de preferencia para la web de la Biblioteca Cochrane.

Idioma de la Revisión Cochrane

Idioma de la web

Referencias

Referencias de los estudios excluidos de esta revisión

Aksamit 2016 {published data only}

Aksamit 2017 {published data only}

Alberto 1968 {published data only}

Alekseenko 1978 {published data only}

Alekseenko 1980 {published data only}

Aliberti 2016 {published data only}

Al‐Mobeireek 1998 {published data only}

Antoniu 2013 {published data only}

Cherniack 1959 {published data only}

ChiCTR‐IOR‐16008910 2016 {published data only}

Chonabayasi 1988 {published data only}

Choo 2018 {published data only}

Cseri 1975 {published data only}

Currie 1987 {published data only}

Dimakou 2017 {published data only}

Douglas 1957 {published data only}

Hayashi 1989 {published data only}

Hill 1992 {published data only}

Howie 1976 {published data only}

Huang 2018 {published data only}

Hughes 1973 {published data only}

Iglauer 1973 {published data only}

Inoue 1989 {published data only}

Irabu 1989 {published data only}

Irabu 1992 {published data only}

Juthong 2011 {published data only}

Kanai 1963 {published data only}

Kawano 1974 {published data only}

Kawashima 1989 {published data only}

Koyama 1992 {published data only}

Krawczyk 1981 {published data only}

Kudo 1992 {published data only}

Kurishima 1992 {published data only}

Kuze 1988 {published data only}

Lamotte 1981 {published data only}

Ledson 2000 {published data only}

Lunacharskaia 1968 {published data only}

Maekawa 1967 {published data only}

Masuno 1992 {published data only}

Matsumoto 1984 {published data only}

Matsumoto 1992 {published data only}

Matsuura 1993 {published data only}

May 1974 {published data only}

Mazzei 1993 {published data only}

Messens 1973 {published data only}

Milcev 1985 {published data only}

Ming 2005 {published data only}

Molodtsova 1980 {published data only}

Morrone 1989 {published data only}

Murayama 1992 {published data only}

Nagy 1968 {published data only}

Nakagawa 1989 {published data only}

Nakagawa 1993 {published data only}

Nasu 1988 {published data only}

NCT00415350 {published data only}

NCT00524095 {published data only}

NCT00775138 {published data only}

NCT00889967 {published data only}

NCT00930982 {published data only}

NCT01313624 {published data only}

NCT01515007 {published data only}

NCT01538667 {published data only}

NCT01761214 {published data only}

NCT02035488 {published data only}

NCT02047773 {published data only}

NCT02081963 {published data only}

NCT02102152 {published data only}

NCT02104245 {published data only}

NCT02107274 {published data only}

NCT02315547 {published data only}

NCT02491723 {published data only}

NCT02509091 {published data only}

NCT02657473 {published data only}

NCT02661438 {published data only}

NCT03058718 {published data only}

NCT03093974 {published data only}